Compare UXIN & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UXIN | YDES |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | China | Taiwan |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 543.0M |
| IPO Year | 2018 | N/A |
| Metric | UXIN | YDES |
|---|---|---|
| Price | $1.76 | $2.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 163.4K | 19.4K |
| Earning Date | 04-10-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $245.77 | N/A |
| Revenue Next Year | $44.72 | N/A |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.71 | $2.38 |
| 52 Week High | $5.32 | $25.00 |
| Indicator | UXIN | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 30.27 | 34.74 |
| Support Level | N/A | N/A |
| Resistance Level | $3.18 | $5.36 |
| Average True Range (ATR) | 0.17 | 0.44 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 5.63 | 23.84 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.